Navigation Links
Beckman Coulter to Present at the Morgan Stanley Healthcare Unplugged Conference
Date:8/22/2008

ORANGE COUNTY, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, announced today that Paul Glyer, Beckman Coulter's senior vice president of Corporate Strategy and Business Development, will present at the Morgan Stanley Healthcare Unplugged Conference on Tuesday, September 9, 2008 at 3:55 p.m. (ET).

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

The live webcast of Beckman Coulter's presentation can be accessed by visiting their website at http://www.beckmancoulter.com. To access the webcast select "go to IR" under Investor Relations and find the event listed under "What's Ahead." The webcast will be archived on the company's website for future on-demand replay through Tuesday, October 28, 2008.

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represent more than 78 percent of the company's 2007 revenue of $2.76 billion. For more information, visit http://www.beckmancoulter.com.

Contact: Cynthia Skoglund (714) 773-8213

Manager, Investor Relations


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter to Present at the Thomas Weisel Healthcare Conference 2008
2. Beckman Coulter Announces Second Quarter 2008 Results
3. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
4. Upcoming Beckman Coulter Investor Events Second Half of 2008
5. Beckman Coulter to Present at Upcoming Healthcare Conferences
6. Beckman Coulter Announces First Quarter 2008 Results
7. Beckman Coulter Acquires Rights to Hepatitis C Virus
8. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
9. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
10. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
11. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
(Date:3/22/2017)... 22, 2017   iSpecimen ®, the ... Doctors Pathology Service (DPS), a full-service anatomic pathology ... the United States , has joined a program ... Network (DHIN) to make human biospecimens and associated ... novel program, announced in 2015 as a collaboration between ...
(Date:3/22/2017)... 2017   Boston Biomedical , an industry leader ... target cancer stemness pathways, today announced its Board of ... Chief Executive Officer, effective April 24, 2017. ... , M.D., FACP, who has led Boston Biomedical since ... leadership, Boston Biomedical has grown from a "garage startup" ...
(Date:3/22/2017)... Yorba Linda, Ca (PRWEB) , ... March 21, ... ... immunogenicity, and clearance of biologics. To acquire information on the desired increase and/or ... in the biopharmaceutical industry for rapid N-glycosylation profiling of therapeutic antibodies. , ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
Breaking Biology News(10 mins):